Item 7.01 Regulation FD Disclosure

On January 9, 2022, Century Therapeutics, Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.




Item 8.01 Other Events

On January 5, 2023, the Company issued a press release announcing its plan for internal portfolio prioritization to extend its cash runway into 2026. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits






(d) Exhibits



Exhibit
No.                                           Document

  99.1       Investor Presentation of Century Therapeutics, Inc., dated January 9, 2022

  99.2       Press Release of Century Therapeutics, Inc., dated January 5, 2023

104        Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses